{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:08:12Z","timestamp":1767139692581,"version":"build-2238731810"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Carl Gustav Carus University Hospital of the Technical University Dresden"},{"name":"Klinikum Chemnitz gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00432-021-03702-7","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T14:02:15Z","timestamp":1624716135000},"page":"1171-1181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4\u00a0years"],"prefix":"10.1007","volume":"148","author":[{"given":"Sabine","family":"K\u00fcrzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-6894","authenticated-orcid":false,"given":"Andr\u00e9-Ren\u00e9","family":"Blaudszun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilly","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-7580","authenticated-orcid":false,"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Birkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Schaefer-Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-0422","authenticated-orcid":false,"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-3275","authenticated-orcid":false,"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"3702_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-136659","volume":"136","author":"R Bannerji","year":"2020","unstructured":"Bannerji R, Allan JN, Arnason JE, Brown JR, Advani R, Ansell SM, O\u2019Brien SM, Duell J, Martin P, Joyce RM, Li J, Flink DM, Zhu M, Weinreich DM, Yancopoulos GD, Sirulnik A, Chaudhry A, Ambati SR, Topp MS (2020) Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood 136:42\u201343. https:\/\/doi.org\/10.1182\/blood-2020-136659","journal-title":"Blood"},{"key":"3702_CR2","unstructured":"Borchmann P (2020) Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma: final results of the international, randomized phase III HD17 trial by the GHSG. EHA Library:S101"},{"key":"3702_CR3","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, H\u00fcttmann A, Dierlamm J, Soekler M, Beck H-J, Willenbacher W, Ludwig W-D, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, K\u00fchnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A (2017) PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:2790\u20132802. https:\/\/doi.org\/10.1016\/S0140-6736(17)32134-7","journal-title":"Lancet"},{"key":"3702_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35:2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"key":"3702_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244","journal-title":"J Clin Oncol"},{"key":"3702_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ (2021) Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med 384:673\u2013674. https:\/\/doi.org\/10.1056\/NEJMc2030164","journal-title":"N Engl J Med"},{"key":"3702_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"key":"3702_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378:331\u2013344. https:\/\/doi.org\/10.1056\/NEJMoa1708984","journal-title":"N Engl J Med"},{"key":"3702_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-141117","volume":"136","author":"L Coyle","year":"2020","unstructured":"Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness C, Desai R, Mergen N (2020) Updated analysis of an open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Blood 136:14\u201315. https:\/\/doi.org\/10.1182\/blood-2020-141117","journal-title":"Blood"},{"key":"3702_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, van den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620Accessed 14 April 2021","journal-title":"Blood"},{"issue":"Suppl 9","key":"3702_CR11","doi-asserted-by":"publisher","first-page":"ix71","DOI":"10.1093\/annonc\/mdm297","volume":"18","author":"V Diehl","year":"2007","unstructured":"Diehl V, Fuchs M (2007) Early, intermediate and advanced Hodgkin\u2019s lymphoma: modern treatment strategies. Ann Oncol 18(Suppl 9):ix71\u2013ix79. https:\/\/doi.org\/10.1093\/annonc\/mdm297","journal-title":"Ann Oncol"},{"key":"3702_CR12","unstructured":"Dorai-Raj S (2014) Binom: binomial confidence intervals for several parameterizations. https:\/\/CRAN.R-project.org\/package=binom. Accessed 14 Apr 2021"},{"key":"3702_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143\u2013151","journal-title":"Biometrics"},{"key":"3702_CR14","volume-title":"An R companion to applied regression","author":"J Fox","year":"2019","unstructured":"Fox J, Weisberg S (2019) An R companion to applied regression, 3rd edn. SAGE Publications Inc, Thousand Oaks","edition":"3"},{"key":"3702_CR15","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"3702_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","volume":"15","author":"B Glass","year":"2014","unstructured":"Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, G\u00f6rlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N (2014) Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 15:757\u2013766. https:\/\/doi.org\/10.1016\/S1470-2045(14)70161-5","journal-title":"Lancet Oncol"},{"key":"3702_CR17","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v040.i03","author":"G Grolemund","year":"2011","unstructured":"Grolemund G, Wickham H (2011) Dates and times made easy with lubridate. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v040.i03","journal-title":"J Stat Softw"},{"key":"3702_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s002779900150","volume":"79","author":"M H\u00e4nel","year":"2000","unstructured":"H\u00e4nel M, Kr\u00f6ger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, H\u00e4nel A, Kr\u00fcger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR (2000) ASHAP\u2013an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79:304\u2013311. https:\/\/doi.org\/10.1007\/s002779900150","journal-title":"Ann Hematol"},{"key":"3702_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s004320000226","volume":"127","author":"M H\u00e4nel","year":"2001","unstructured":"H\u00e4nel M, Kr\u00f6ger N, Kroschinsky F, Birkmann J, H\u00e4nel A, Herbst R, Naumann R, Friedrichsen K, Ehninger G, Zander AR, Fiedler F (2001) Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. J Cancer Res Clin Oncol 127:387\u2013395. https:\/\/doi.org\/10.1007\/s004320000226","journal-title":"J Cancer Res Clin Oncol"},{"key":"3702_CR20","unstructured":"Harrell Jr FE, with contributions from Charles Dupont, many others (2015) Hmisc: Harrell miscellaneous. https:\/\/CRAN.R-project.org\/package=Hmisc. Accessed 14 Apr 2021"},{"key":"3702_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med 339:1506\u20131514. https:\/\/doi.org\/10.1056\/NEJM199811193392104","journal-title":"N Engl J Med"},{"key":"3702_CR22","unstructured":"Hothorn T, Hornik K (2019) exactRankTests: exact distributions for rank and permutation tests. https:\/\/CRAN.R-project.org\/package=exactRankTests. Accessed 14 Apr 2021"},{"key":"3702_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL (2015) Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93:290\u2013296. https:\/\/doi.org\/10.1038\/icb.2014.93","journal-title":"Immunol Cell Biol"},{"key":"3702_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"3702_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-134362","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Rossi JM, Bot A, Zheng L, Vezan R, Bashir Z, Kim JJ, Chu R, Neelapu SS (2020) Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood 136:40\u201342. https:\/\/doi.org\/10.1182\/blood-2020-134362","journal-title":"Blood"},{"key":"3702_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2020-137045","volume":"136","author":"U Jaeger","year":"2020","unstructured":"Jaeger U, Bishop MR, Salles G, Schuster SJ, Maziarz RT, Han X, Savchenko A, Roscoe N, Orlando E, Knoblock D, Tiwari R, Bubuteishvili Pacaud L, Corradini P (2020) Myc expression and tumor-infiltrating T cells are associated with response in patients (Pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the juliet trial. Blood 136:48\u201349. https:\/\/doi.org\/10.1182\/blood-2020-137045","journal-title":"Blood"},{"key":"3702_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1200\/JCO.2002.20.1.221","volume":"20","author":"A Josting","year":"2002","unstructured":"Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 20:221\u2013230. https:\/\/doi.org\/10.1200\/JCO.2002.20.1.221","journal-title":"J Clin Oncol"},{"key":"3702_CR28","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, M\u00fcller H, Borchmann P, Baars JW, Metzner B, D\u00f6hner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Sch\u00e4fer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann M-L, Raemaekers J, Engert A (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol 28:5074\u20135080. https:\/\/doi.org\/10.1200\/JCO.2010.30.5771","journal-title":"J Clin Oncol"},{"key":"3702_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Josting A, M\u00fcller H, Borchmann P, Baars JW, Metzner B, D\u00f6hner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Sch\u00e4fer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann M-L, Raemaekers J, Engert A (2010) Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol 28:5074\u20135080. https:\/\/doi.org\/10.1200\/JCO.2010.30.5771","journal-title":"Lancet Oncol"},{"key":"3702_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2019-121460","volume":"134","author":"P Lugtenburg","year":"2019","unstructured":"Lugtenburg P, Mous R, Clausen MR, Chamuleau ME, Johnson P, Linton K, Rule S, Oliveri RS, DeMarco D, Hiemstra IH, Chen G, Azaryan A, Gupta M, Ahmadi T, Hutchings M (2019) First-in-human, phase 1\/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody\u00ae-CD3\u00d7CD20) in B-cell non-Hodgkin lymphomas. Blood 134:758. https:\/\/doi.org\/10.1182\/blood-2019-121460","journal-title":"Blood"},{"key":"3702_CR31","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","volume":"1","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P, Wright KT, Rodig SJ (2017) Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv 1:2643\u20132654. https:\/\/doi.org\/10.1182\/bloodadvances.2017012534","journal-title":"Blood Adv"},{"key":"3702_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/EDBK_238799","volume":"39","author":"AJ Moskowitz","year":"2019","unstructured":"Moskowitz AJ, Herrera AF, Beaven AW (2019) Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy. Am Soc Clin Oncol Educ Book 39:477\u2013486. https:\/\/doi.org\/10.1200\/EDBK_238799","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3702_CR33","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol 38:3119\u20133128. https:\/\/doi.org\/10.1200\/JCO.19.02104","journal-title":"J Clin Oncol"},{"key":"3702_CR34","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2019-125792","volume":"134","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, van den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C (2019) A comparison of two-year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory large B cell lymphoma. Blood 134:4095. https:\/\/doi.org\/10.1182\/blood-2019-125792","journal-title":"Blood"},{"key":"3702_CR35","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Kloess M, Schmits R, Feller AC, R\u00fcbe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634\u2013641. https:\/\/doi.org\/10.1182\/blood-2003-06-2095","journal-title":"Blood"},{"key":"3702_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, \u00d6sterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P-L, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, L\u00f3pez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391. https:\/\/doi.org\/10.1016\/S1470-2045(06)70664-7","journal-title":"Lancet Oncol"},{"key":"3702_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Tr\u00fcmper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105\u2013116. https:\/\/doi.org\/10.1016\/S1470-2045(08)70002-0","journal-title":"Lancet Oncol"},{"key":"3702_CR38","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20131545. https:\/\/doi.org\/10.1056\/NEJM199512073332305","journal-title":"N Engl J Med"},{"key":"3702_CR39","unstructured":"R Core Team (2020) R: a language and environment for statistical computing. https:\/\/www.R-project.org\/. Accessed 14 Apr 2021"},{"key":"3702_CR40","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1182\/blood.V93.11.3632","volume":"93","author":"J Rodriguez","year":"1999","unstructured":"Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB (1999) ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin\u2019s disease. Blood 93:3632\u20133636","journal-title":"Blood"},{"key":"3702_CR41","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M\u00fcller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet 359:2065\u20132071. https:\/\/doi.org\/10.1016\/S0140-6736(02)08938-9","journal-title":"Lancet"},{"key":"3702_CR42","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002\u20131). Lancet Oncol 13:1250\u20131259. https:\/\/doi.org\/10.1016\/S1470-2045(12)70481-3","journal-title":"Lancet Oncol"},{"key":"3702_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bartlett NL, Assouline S, Yoon S-S, Bosch F, Sehn LH, Cheah CY, Shadman M, Gregory GP, Ku M, Wei MC, Yin S, Kwan A, Yousefi K, Hernandez G, Li C-C, O\u2019Hear C, Budde LE (2019a) Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 134:6. https:\/\/doi.org\/10.1182\/blood-2019-123742","journal-title":"Blood"},{"key":"3702_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, J\u00e4ger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak \u00d6, Salles G, Maziarz RT (2019b) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"3702_CR45","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"3702_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38:155\u2013165. https:\/\/doi.org\/10.1200\/JCO.19.00172","journal-title":"J Clin Oncol"},{"key":"3702_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11912-019-0809-z","volume":"21","author":"S Shanbhag","year":"2019","unstructured":"Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ (2019) Is it time to revisit the role of allogeneic transplantation in lymphoma? Curr Oncol Rep 21:65. https:\/\/doi.org\/10.1007\/s11912-019-0809-z","journal-title":"Curr Oncol Rep"},{"key":"3702_CR48","unstructured":"Signorell A et al (2020) DescTools: tools for descriptive statistics. https:\/\/cran.r-project.org\/package=DescTools. Accessed 14 Apr 2021"},{"key":"3702_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s11864-014-0287-3","volume":"15","author":"A Sureda","year":"2014","unstructured":"Sureda A, Domenech E, Schmitz N, Dreger P (2014) The role of allogeneic stem cell transplantation in Hodgkin\u2019s lymphoma. Curr Treat Options Oncol 15:238\u2013247. https:\/\/doi.org\/10.1007\/s11864-014-0287-3","journal-title":"Curr Treat Options Oncol"},{"key":"3702_CR50","unstructured":"Therneau TM (2015) A package for survival analysis in R. https:\/\/CRAN.R-project.org\/package=survival. Accessed 14 Apr 2021"},{"key":"3702_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York"},{"key":"3702_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117\u2013122","journal-title":"Blood"},{"key":"3702_CR53","first-page":"138a","volume":"82","author":"WS Velasquez","year":"1993","unstructured":"Velasquez WS, Dunphy F, Santillana S, Adkins D, Bowers C, Broun GO Jr, Petruska PJ, Spitzer G (1993) ASHAP, an effective treatment for relapsing and refractory Hodgkin\u2019s disease (HD) and non-Hodgkin\u2019s lymphoma (NHL). Blood 82:138a (abstr 538)","journal-title":"Blood"},{"key":"3702_CR54","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"WS Velasquez","year":"1994","unstructured":"Velasquez WS, Dunphy F, Santillana S, Adkins D, Bowers C, Broun GO Jr, Petruska PJ, Spitzer G (1993) ASHAP, an effective treatment for relapsing and refractory Hodgkin\u2019s disease (HD) and non-Hodgkin\u2019s lymphoma (NHL). Blood 82:138a (abstr 538)","journal-title":"J Clin Oncol"},{"key":"3702_CR55","doi-asserted-by":"publisher","unstructured":"Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169\u20131176. https:\/\/doi.org\/10.1200\/JCO.1994.12.6.1169","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"3702_CR565","doi-asserted-by":"crossref","unstructured":"Venables WN, Ripley BD (2002) Modern applied statistics with S with 152 illustrations, 4th edn. Statistics and computing. Springer, New York. Accessed 14 Apr 2021","DOI":"10.1007\/978-0-387-21706-2"},{"key":"3702_CR56","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","volume":"5","author":"B von Tresckow","year":"2018","unstructured":"von Tresckow B, Kreissl S, Goergen H, Br\u00f6ckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, B\u00fcrkle C, Baues C, Diehl V, Engert A, Borchmann P (2018) Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol 5:e462\u2013e473. https:\/\/doi.org\/10.1016\/S2352-3026(18)30140-6","journal-title":"Lancet Haematol"},{"key":"3702_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: elegant graphics for data analysis. Springer-Verlag, New York"},{"key":"3702_CR58","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MGM, Ligon AH, Engert A (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1007\/s00432-022-04324-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000}}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03702-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03702-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03702-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T02:10:00Z","timestamp":1662775800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03702-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3702"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03702-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"15 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00432-022-04324-3","URL":"https:\/\/doi.org\/10.1007\/s00432-022-04324-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Eligible patients were registered at the Medical and Outpatient\u2019s clinic I of the Carl Gustav Carus University Hospital of the Technical University Dresden, where the trial was designed and approved by the local ethics committee in 2001 (11 January 2001; number of registration: EK155102000).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study. In addition, all the authors consented the last version of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}